Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $120.7 million.

  • Beam Therapeutics' Share-based Compensation fell 23.05% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year decrease of 8.00%. This contributed to the annual value of $120.7 million for FY2024, which is 22.32% up from last year.
  • Latest data reveals that Beam Therapeutics reported Share-based Compensation of $120.7 million as of FY2024, which was up 22.32% from $98.6 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Share-based Compensation ranged from a high of $120.7 million in FY2024 and a low of $15.4 million during FY2020.
  • Its 3-year average for Share-based Compensation is $101.2 million, with a median of $98.6 million in 2023.
  • Data for Beam Therapeutics' Share-based Compensation shows a peak YoY soared of 183.29% (in 2021) over the last 5 years.
  • Beam Therapeutics' Share-based Compensation (Yearly) stood at $15.4 million in 2020, then soared by 183.29% to $43.6 million in 2021, then spiked by 93.53% to $84.3 million in 2022, then climbed by 16.99% to $98.6 million in 2023, then rose by 22.32% to $120.7 million in 2024.